In a bid to facilitate the modernization of the clinical trial process for innovative cancer treatments, U.S. Food and Drug Administration Commissioner Scott Gottlieb says payers need to boost their data sharing efforts, the American Journal of Managed Care reports.
Gottlieb made the call for more robust data sharing during the National Comprehensive Cancer Network Policy Conference in Washington.
According to the AJMC report, Gottlieb said there were four policy areas joined by “the need to modernize drug development to harness the full medical potential of this rapidly advancing science, while ensuring that innovation remains affordable for patients.”
The FDA could also take steps to trim time and costs from the drug approval process, all while promoting competition and creating a better environment for generic and biosimilar development.
“If FDA-approved drugs are priced out of reach of patients, then the full benefits of innovation won’t be realized,” Gottlieb said.
